The future of AML treatment? Progress in IDH1/2 inhibitors for AML
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al.
Multiple myeloma: genomic evolution
Jonathan Keats et al.
Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF